BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.770
-0.260 (-12.81%)
At close: Jun 27, 2025, 4:00 PM
1.860
+0.090 (5.08%)
After-hours: Jun 27, 2025, 7:39 PM EDT
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -91.62% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover BioXcel Therapeutics stock have a consensus rating of "Buy" and an average price target of $34.6, which forecasts a 1854.8% increase in the stock price over the next year. The lowest target is $4 and the highest is $80.
Price Target: $34.6 (+1854.8%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $8 | Strong Buy | Maintains | $3 → $8 | +351.98% | Jun 23, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +3,572.32% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $48 | Strong Buy | Maintains | $80 → $48 | +2,611.86% | Jan 30, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $112 → $4 | Strong Buy → Sell | Downgrades | $112 → $4 | +125.99% | Jan 7, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +4,419.77% | Jan 6, 2025 |
Financial Forecast
Revenue This Year
2.38M
from 2.27M
Increased by 5.03%
Revenue Next Year
9.31M
from 2.38M
Increased by 291.01%
EPS This Year
-8.59
from -23.51
EPS Next Year
-7.14
from -8.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.7M | 17.4M | 125.2M | ||
| Avg | 2.4M | 9.3M | 116.6M | ||
| Low | 1.5M | 4.7M | 107.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.8% | 632.4% | 1,245.8% | ||
| Avg | 5.0% | 291.0% | 1,153.3% | ||
| Low | -35.1% | 97.6% | 1,052.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.44 | -2.12 | 3.84 | ||
| Avg | -8.59 | -7.14 | 0.64 | ||
| Low | -9.41 | -11.63 | -2.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.